NUP214 and acute lymphoblastic leukemia: NUP214-ABL1 is sensitive to Imatinib and Nilotinib ABL1 kinase inhibitors and this represents an attractive therapeutic strategy for NUP214-ABL1 positive T-ALL [6, 11].